https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-04264&r=1
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer - NCI
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
early breast cancerphasestudyribociclib
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-11057&r=1
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected...
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
https://scholars.duke.edu/publication/1388320
Scholars@Duke publication: Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled...
https://www.kisqali-hcp.com/
HR+/HER2- eBC & mBC Treatment | KISQALI® (ribociclib) | HCP
hrebcmbctreatmentribociclib
https://www.nice.org.uk/guidance/ta687/chapter/2-Information-about-ribociclib
2 Information about ribociclib | Ribociclib with fulvestrant for treating hormone...
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative,...
information aboutribociclibfulvestranttreatinghormone
https://adisinsight.springer.com/drugsafety/803884478?error=cookies_not_supported&code=06a71c01-eddf-4552-8dc9-a4556c18ad50
Ribociclib - AdisInsight
In a study of 5 patients, conducted between 2017 and 2024, a female patient [age not stated] was described, who developed drug induced liver injury during
ribociclibadisinsight
https://adisinsight.springer.com/drugsafety/803928878?error=cookies_not_supported&code=f356c1bb-c214-4bb1-9e31-c24f896130ea
Ribociclib - AdisInsight
Sixteen women [ages not stated] with hormone receptor-positive, HER2-negative metastatic breast cancer were receiving ribociclib [dose, route and treatment
ribociclibadisinsight
https://adisinsight.springer.com/trials/700302977?error=cookies_not_supported&code=ef0461e9-b94f-4e94-bfba-d5ef133cf5d1
Real-world evidence for the effectiveness, safety and tolerability of Ribociclib + aromatase...
Aim of this real-world study was to assess effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment
real world evidencesafety and tolerabilityfor the
https://ce.massmed.nejm.org/nejm-weekly-cme/content/overall-survival-ribociclib-plus-fulvestrant-advanced-breast-cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | MMS/NEJM Continuing...
advanced breast cancer